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OBJECTIVE: In our current work, in vivo examination of
AQP5 distribution in labial salivary glands following
stimulation of secretion has been carried out in normal
individuals and in patients with Sj€ogren’s syndrome.
SUBJECTS AND METHODS: For this study, we selected
five patients with primary Sj€ogren’s syndrome (mean
age 62.4 ± 10.6 s.d. years) diagnosed in accordance with
the European Cooperative Community classification cri-
teria. There were five patients (mean age 27 ± 2.5 s.d.
years) in the control group. The subcellular distribution
of AQP5 in human labial gland biopsies was determined
with light and immunoelectron microscopy before and
30 min after administration of oral pilocarpine.
RESULTS: In unstimulated control and Sj€ogren’s labial
glands, AQP5 is about 90% localized in the apical
plasma membrane, with only rarely associated gold par-
ticles with intracellular membrane structures. We have
found no evidence of pilocarpine-induced changes in
localization of AQP5 in either healthy individuals or
patients with Sj€ogren’s syndrome.
CONCLUSIONS: Our studies indicate that neither
Sj€ogren’s syndrome itself, nor muscarinic cholinergic
stimulation in vivo caused any significant changes in the
distribution of AQP5 in the labial salivary gland cells.
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Introduction
Sj€ogren’s syndrome (SS) is an autoimmune disease char-
acterized by progressive inﬁltration of exocrine glands by
mononuclear cells, mainly resulting in decreased secre-
tions of salivary glands (xerostomia) and lacrimal glands
(xerophthalmia) (Carpenter et al, 2000; Jonsson et al,
2001; Fox, 2005). In human minor and major salivary
glands, AQP5 is abundantly localized to the apical plasma
membrane domains of acinar cells and not detected in the
duct cells (Gresz et al, 2001).
In the symptomatic treatment for xerostomia, oral pilo-
carpine has been used to increase salivary secretion (Fox
et al, 1991, 2001; Rhodus, 1997; Vivino et al, 1999;
Nyarady et al, 2006). At 30, 60, and 90 min after drug
intake, salivary ﬂow rate signiﬁcantly increased with a
peak salivary ﬂow occurring approximately 60 min after
drug intake. The main adverse effect was sweating. Five-
milligram pilocarpine tablets/day improved symptoms
signiﬁcantly.
Examination of AQP5 distribution in intracellular struc-
tures and apical plasma membrane of the human labial sa-
livary gland cells following stimulation of secretion have
not previously been performed in vivo. Discrepancies in
the literature regarding AQP5-localization in human sali-
vary tissue were challenging to us (Ishikawa et al, 1998,
1999, 2000, 2002, 2004, 2005; Tada et al, 1999; Ishikawa
and Ishida, 2000; Beroukas et al, 2001; Steinfeld et al,
2001, 2002; Steinfeld and Delporte, 2002; Waterman
et al, 2002, 2003; Matsuzaki et al, 2003; Gresz et al,
2004; Li et al, 2004, 2006; Delporte and Steinfeld, 2006;
Xiao et al, 2011). The aim of this study was to determine
the effect of oral pilocarpine on the localization of AQP5
in human labial minor salivary glands of normal and
patients with SS using light microscopy and immunogold
electron microscopy with different types of anti-human
AQP5 antibodies. To show the earliest events in salivary
secretion, a stimulation time of 30 min was chosen.
According to the data in the literature, in our current
work, we chose a time point where the concentration of
AQP5 is the highest at the place of its basic function, that
is, at the place of water secretion, namely at the apical
membrane. This was 30 min after stimulation with pilo-
carpine. At 90 min, a decrease in secretion has already
been observed (Vivino et al, 1999).
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Materials and methods
Diagnosis of patients with SS
In accordance with the World Medical Association Decla-
ration of Helsinki (version 2002), the study was performed
and all participants signed informed consent forms. The
procedures were approved by the Semmelweis University
Regional Committee of Science and Research Ethics (TU-
KEB 153/2012). The trial was accomplished by the Good
Clinical Practice norms. Symptoms were assessed by ques-
tionnaires. Every conditions where the use of pilocarpine
would be contraindicated were excluded. Five patients
with primary SS (mean age 62.4  10.6 s.d. years, range
53–74 years) were selected and diagnosed according to
the European Cooperative Community classiﬁcation crite-
ria (Vitali et al, 2002). Keratoconjunctivitis sicca and
xerostomia were evaluated. After measuring whole-mouth
salivary ﬂow rates, labial salivary gland biopsies were
taken. Less than 0.4 ml/min of unstimulated salivary ﬂow
rate was considered as salivary hypofunction and less or
equal than 0.1 ml/min as xerostomia (Skopouli et al,
1989). The diagnosis of SS was conﬁrmed by positive test
results (Table 1).
The control ﬁve patients (mean age 27  2.5 s.d. years,
range 24–31 years) were having treatment for mucocele
(mucous cyst) inside the lower lip and had no evidence of
SS.
Labial gland biopsy and salivary stimulation with oral
pilocarpine
Labial gland biopsies were made as in Daniels for routine
diagnosis of Sj€ogren’s syndrome (Daniels, 1984, 1986).
The biopsy samples were diagnosed by an expert in pri-
mary SS pathology in a blinded manner. A positive diag-
nosis of SS was made with focus scores >1 (Vitali et al,
2002). After unstimulated labial glands had been removed
from both sets of patients, salivary secretion was induced
by oral pilocarpine (5 mg tablet, Salagen, pilocarpinhydro-
chlorid, Novartis Pharma GmbH, 90327 N€urnberg, OGYI-
T-5479) (Wynn, 1996; Salagen tablets, 1997) for 30 min,
and then additional labial glands were excised. Finally, the
wound was subsequently closed with single sutures (non-
absorbable polyamide monoﬁlament 6.0, Braun AG, Ger-
many). After uneventful healing, the stitches were
removed at 4–7 days postoperative.
Antibodies
Previously characterized, afﬁnity-puriﬁed polyclonal anti-
bodies to human AQP5 were used in our immunohisto-
chemical studies: One was provided by Professor Peter
Agre (Johns Hopkins University, Baltimore, USA), and
the other one was developed against the 20 amino acids
of the C-terminal of human AQP5 (that is different from
mouse and rat C-terminals).
Immunohistochemical procedure for light microscopy
(Gresz et al, 2004)
Brieﬂy biopsy samples of individual labial glands were
transferred into cold 4% paraformaldehyde (in 0.1 M PBS,
pH 7.4), stored for 24 h or more, dehydrated in ethanol and
xylene, and embedded in parafﬁn. Two-micrometer-thick
sections were dewaxed and rehydrated. Immunoperoxidase
labeling was performed. After overnight incubation with
primary antibody at 4°C, sections were rinsed and labeling
was visualized with goat anti-rabbit secondary antibodies
conjugated with horseradish peroxidase. After washing in
PBS, sections were counterstained in Mayers hematoxylin
for 1 min, rinsed, dehydrated, and mounted. Photomico-
graphs were taken with an Eclipse E-600 (Nikon, Melville,
NY, USA) TMS phase-contrast microscope.
Immunohistochemical procedure for immunoelectron
microscopy (Gresz et al, 2004)
For immunoelectron microscopy, the samples were prepared
and treated as in our previous studies described in details
before (Nielsen et al, 1995, 1997; Yasui et al, 1999; Kwon
et al, 2000; Gresz et al, 2004). Brieﬂy, after freeze-substitu-
tion, equilibration over 3 days in 0.5% uranyl acetate–meth-
anol, and rinsing in methanol, the samples were inﬁltrated
with Lowicryl HM20 followed by UV polymerization. Ul-
trathin Lowicryl HM20 sections were pretreated, rinsed, and
labeled with anti AQP-5 antibody diluted 1:200, and incu-
bated overnight at 4°C. Sections were then rinsed and incu-
bated at room temperature for an hour with goat anti-rabbit
IgG conjugated to gold particles of 10 nm diameter. After
staining with uranyl acetate and lead citrate, sections were
examined in Philips CM100 electron microscope (Eindho-
ven, the Netherlands). Quantitation of the electron micro-
graphs was performed. Labial glands from 5 to 5 patients
from each group were investigated blindly. The number of
gold particles associated with the apical membrane or with
intracellular structures was determined per cell.
Results
Normal subjects
Immunoperoxidase labeling with human AQP5 antibodies
was performed on parafﬁn sections of human labial sali-
vary glands. They did not cross-react with rat salivary
gland tissue (data not shown) and they gave the same
labeling pattern (Figure 1). AQP5 labeling was observed
apically in the acinar cells including the membranes of the
secretory canaliculi in a punctate appearance (Figure 1a).
No AQP5 labeling was present in the ducts of the labial
glands (e.g., D in Figure 1a).
The subcellular localization of AQP5 in human labial sal-
ivary glands was further investigated by immunoelectron
Table 1 Diagnostics of the patients with Sj€ogren’s syndrome
Gender Age
Sialometry
(unstimulated
whole-mouth
salivary ﬂow
rate ml/min)
Schirmer
tear test
(<7 mm/
5 min)
Histology
(focus
score >1)
Anti-SS-A
or anti-SS-B
antibodies
(at a titer of
1:160 or
greater)
S1 F 74 0.01 0.5 3 +
S2 F 53 0.05 0.1 2 +
S3 F 55 0.26 3.25 1–2 +
S4 F 74 0.01 1.75 7 +
S5 F 56 0.05 2.75 1–2 +
SS, Sj€ogren’s syndrome.
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microscopy. A quantitative assessment of immunogold
labeling on sections from ﬁve different patients showed that
gold particles were few in number in intracellular structures
[9.9  0.8% (mean  s.e.m.)], they were mainly associ-
ated with the apical plasma membranes (Figure 1c, d),
especially with the microvilli [90.1  0.8% (mean 
s.e.m.)].
Salivary secretion was stimulated by administration of a
pilocarpine tablet (5 mg) for 30 min. Light microscope
immunohistochemistry (Figure 1b) and immunoelectron
microscopy (Figure 1e) revealed that there were no signiﬁ-
cant changes in the distribution of AQP5. On average, the
level of intracellular labeling remained almost the same
(9.6  0.8%), and the other gold particles (90.4  0.8%)
were associated with the apical plasma membrane in a
punctate appearance that can be a result of clustering of
AQP5, around the area of the microvilli. Thus, in control
human labial salivary glands, no indication of changes can
be observed in distribution of AQP5 after stimulation with
oral pilocarpine.
Patients with SS
Distribution and localization of AQP5 in human labial
minor salivary glands were the same in patients with SS as
in the controls. We have used the same human AQP5
antibodies as on normal subjects and they gave the same
labeling pattern also in patients with SS (Figure 2). AQP5
was deﬁnitely localized in the apical plasma membranes of
acinar cells (Figure 2a). Thus, in patients with Sj€ogren’s
syndrome, almost the same subcellular localization pattern
of AQP5 was found: 91.8  1.4% (mean  s.e.m.) of the
gold particles were present in the apical plasma membrane,
and only 8.2  1.4% (mean  s.e.m.) at the intracellular
structures (Figure 2c).
The muscarinic stimulation for 30 min signiﬁcantly
increased saliva production, as it was nearly undetectable
without stimulation (data not shown). Immunohistochemis-
try demonstrated that even after pilocarpine treatment, the
AQP5 labeling remained localized to the apical plasma
membrane of the acinar cells (Figure 2b). It was con-
ﬁrmed by immunoelectron microscopy: 91.9  0.5%
(mean  s.e.m.) of gold particles were present in the api-
cal plasma membrane, including the microvilli, and
8.1  0.5% (mean  s.e.m.) were present in the intracel-
lular compartments (Figure 2d).
Discussion
In this study, we have tested the effect of oral pilocarpine
on AQP5 distribution in human labial salivary gland biop-
sies of control and patients with Sj€ogren’s syndrome
before dosing and 30 min after drug exposure with light
microscopy and immunogold electron microscopy.
Corresponding with our previous results on human sali-
vary glands (Gresz et al, 2001), AQP5 labeling was
clearly apical at the acinar membrane domains, and no
AQP5 labeling was present in the ducts of the labial
glands (e.g., D in Figure 1a). In line with the results of
Beroukas et al, (2001) (Waterman et al, 2002, 2003),
AQP5 was localized apically in the acinar cells of patients
(a) (b)
(c) (e)
(d)
Figure 1 AQP5 distribution in human labial salivary glands of normal subjects by immunohistochemistry. Immunoperoxidase light microscopical and
immunogold electron microscopical localization of AQP5 under unstimulated (a, c, d) and stimulated (b, e) conditions of salivary secretion. (a) In
unstimulated normal human labial glands, AQP5 labeling is associated exclusively with the apical membrane of acinar cells (arrows), and it is absent in
the ducts (D). (c) Low magniﬁcation shows two adjacent cells of a human labial gland acinus. (d) Gold particles are associated with microvilli of the
apical membrane and of intercellular secretory canaliculi (arrows) in the acini. (b) Immunolocalization of AQP5 30 min after administration of oral pilo-
carpine. The localization pattern is similar to that in normal tissues (panel a). (e) Immunogold electron microscopic localization of AQP5 after 30-min
oral pilocarpine administration. Compared with control tissues (Panels c, d), the subcellular localization of AQP5 has not changed. Immunogold labeling
can be observed on microvilli of the acinar lumen (arrows). Cells labeled with 1 and 2 are two adjacent cells; G, secretory granule; L, lumen; N,
nucleus; TJ, tight junction. Magniﬁcations: 9200 (a); 9260 (b); 98.200 (c)
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with Sj€ogren’s syndrome. However, our ﬁnding for the
distribution and density of AQP5 in human labial minor
salivary glands was contrast to the results in other papers
(Steinfeld et al, 2001; Steinfeld et al, 2002; Steinfeld and
Delporte, 2002; Xiao et al, 2011) They claim that AQP5
labeling was present also at the basolateral membrane of
acinar cells in patients with SS (Steinfeld et al, 2001,
2002), not to say that a more recent study reported about
surprising localizations of AQP5 in human labial glands
(Xiao et al, 2011), where an abundance of staining at
nearly every structure of human labial glands including
different types of ducts was shown in controls. However,
the possibility of non-speciﬁc immunohistochemical bind-
ings arises, for their immunohistochemical results particu-
larly claiming that there is a change in distribution of
AQP5 in the labial glands of patients with SS.
Reacting on the contradictions, Beroukas et al, and
Waterman et al, published a paper (Waterman et al, 2002)
and then a longer letter (Waterman et al, 2003) and con-
ﬁrmed our results (Gresz et al, 2001). They concluded
that basolateral staining of AQP5 in salivary acini is non-
speciﬁc background staining, and they were unable to
demonstrate any altered AQP5 expression in Sj€ogren’s
salivary glands.
The contradictory data may have been caused by the
use of different AQP5 antibodies, because anti-rat AQP5
antibody does not cross-react with the human AQP5 pro-
tein (Steinfeld et al, 2002; Delporte and Steinfeld, 2006).
We have tested different human antibodies, and our results
have conﬁrmed an exclusive apical labeling of AQP5 in
Sj€ogren’s labial minor salivary glands.
Another controversial issue is the possibility that the
distribution of AQP5 is altered by trafﬁcking to the apical
membrane. In vitro experiments using gland slices and
cultured cells supported this idea (Ishikawa et al, 1998,
1999, 2000, 2002, 2004, 2005; Tada et al, 1999; Ishikawa
and Ishida, 2000; Li et al, 2004, 2006). We tested this
hypothesis in vivo in rat salivary glands, following stimu-
lation or inhibition of salivary secretion in a previous
study: we have not found evidence of AQP5 transloca-
tion, AQP5 was mainly localized in the apical membrane
structures of the acini and of the intercalated ducts of the
rat submandibular gland, and there was no difference
between controls and treated subjects (Gresz et al, 2004).
The only difference was the clustering of AQP5 at the
apical membrane, especially at the microvilli in stimulated
salivary secretion. It could be explained by the intensive
exocytosis, where clustering seems to be an important
step for apical sorting of proteins (Hannan et al, 1993;
Weisz and Rodriguez-Boulan, 2009). Matsuzaki et al,
(2003, 2006, 2012) have also performed immunoelectron
microscopy in rodent salivary glands to clarify whether
AQP5 is localized intracellularly; however, they were not
able to detect apparent labeling in the cytoplasm, so their
results also suggested that AQP5 translocation is unlikely
to occur.
Similar to our ﬁndings in rat submandibular gland
(Gresz et al, 2004), following pilocarpine administration,
(a) (b)
(c) (d)
Figure 2 AQP5 distribution in human labial salivary glands of Sj€ogren’s syndrome (SS) patients by immunohistochemistry. Immunoperoxidase light
microscopical and immunogold electron microscopical localization of AQP5 under unstimulated (a, c) and stimulated (b, d) conditions of salivary secre-
tion. (a) Large magniﬁcation of a mucous acinus with a serous demilune (marked with *) of a SS patient under resting conditions. AQP5 is associated
with the apical membrane domains (arrows) and is similar to control patients (Figure 1). (c) Electron microscopy shows extensive immunogold labeling
in the apical plasma membrane, especially on microvilli of unstimulated Sj€ogren’s labial glands. (b, d) Immunolocalization of AQP5 30 min after oral
pilocarpine administration. The subcellular localization of AQP5 has not changed as it can be detected by light (b) or immunogold electron microscopy
(d). AQP5 is localized basically in the apical membrane, especially on the microvilli of the acinar lumen (arrows). Magniﬁcations: 9400 (a); 9150 (b)
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the subcellular distribution of AQP5 did not change in
human labial minor salivary glands, either. Our immuno-
electron microscopic ﬁndings supported our light micro-
scopical results showing that the density of gold particles
remained very sparse in intracellular structures both in
normal and in Sj€ogren’s groups. There was no evidence of
AQP5 trafﬁcking after 30-min simulation of salivary
secretion with oral pilocarpine. This suggests that during
stimulated secretion, the accelerated turnover of the apical
membrane happens without movement of AQP5; thus, an
anchoring mechanism is responsible for retaining AQP5 in
the apical membrane. This could cause clustering of
AQP5 labeling after stimulation with pilocarpine, espe-
cially at the microvilli.
In a study, Nielsen et al, suggested that AQP5 is regu-
lated differently in the acinar and interlobular ducts (Ishik-
awa et al, 2005). They proposed that AQP5 translocation
to the apical membrane and dissociation from lipid rafts
takes place at the apical plasma membrane of the interlob-
ular ducts of the rat parotid glands as it arrived there.
Lipid rafts are small, dynamic membrane microdomains
that compartmentalize cellular processes, inﬂuencing
membrane protein and receptor trafﬁcking.
The different authors focus mainly on the distribution
and translocation of AQP5 in unstimulated and stimulated
salivary glands and in Sj€ogren’s syndrome and diabetes,
as well. In the past 10 years, there have been many publi-
cations about the role of AQP5 in salivary secretion, relat-
ing to its distribution and translocation. We consider the
contradictory data originated from the diversity of the
experiments, which were based mainly on rats and mice,
and relatively few of them were carried out on humans.
The contradictions are multiplied by the species differ-
ences, by the type of the salivary glands investigated, by
the different cell types within the glands, and by the dif-
ferences in unstimulated and stimulated conditions. Not
surprisingly Peter Agre, the Nobel Prize winner and father
of AQP-research emphasized ‘Man Is not a rodent: . . .’ in
a title of a paper (King and Agre, 2001).
It is generally accepted that AQP5 is essential for the
movement of water into secretion (Ma et al, 1999). We
know almost nothing about the mechanism of secretion of
AQP5 protein itself into the saliva. The correlation
between mRNA and protein levels of AQP5 is not neces-
sarily parallel. In the parotid glands of diabetic rats, an
increase in AQP5 mRNA and a decrease in AQP5 protein
levels were measured (Wang et al, 2011). The cellular dis-
tribution of AQP5 has been investigated by many workers,
but there are little data about expression, degradation, and
trafﬁcking of AQP5 or any connection between them
(Hoffert et al, 2000; Azlina et al, 2010). One wonders
whether the channels are always open and working. As
there are normal amounts in SS glands, it seems that the
rate of secretion is not dependent on its presence. (Do not
forget that most of all salivary secretion is dependent on
nerve impulses!). A recent study about AQP5 trafﬁcking
in Sj€ogren’s syndrome clearly indicated that autoantibod-
ies against M3 muscarinic receptors inhibit AQP5 translo-
cation from intracellular compartments to the apical
membrane and may lead to decreased salivary secretion
(Lee et al, 2013).
In summary, our studies indicate that AQP5 labeling is
basically associated with the microvilli and the intercellu-
lar secretory canaliculi of the acini in human labial minor
salivary glands, including resting conditions. Neither SS
itself, nor muscarinic cholinergic stimulation resulted in
any signiﬁcant changes in distribution of AQP5 after 30-
min stimulation of salivary secretion. The present AQP5
research leads us to believe that in a few seconds after
stimulation, the possible changes in AQP5-distribution is
not a result of higher level protein synthesis or transloca-
tion, but a result of a cytoskeletal reorganization and
retention of AQP5 in the apical membrane of the acini.
The mechanism is so far undeﬁned, but most likely it is a
critical step in the huge acinar water transport during stim-
ulated salivary secretion. The poor ﬂow of saliva in SS is
not caused by reduced presence of AQP5.
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